Bioverativ, a Sanofi company, is committed to meeting all applicable global transparency requirements, including the Physician Payments Sunshine Act in the United States and other relevant laws, regulations, or agreements. As is our obligation, we record all necessary transfers of value to healthcare professionals and other covered entities and report pursuant to the applicable local codes and laws. We take care to ensure that the data that we submit is as detailed, comprehensive and clear as possible. This information is an important part of our ongoing collaboration with the healthcare community.
The Physician Payments Sunshine Act was passed in March 2010 as part of the Patient Protection and Affordable Care Act in an effort to build transparency into the relationships between physicians and teaching hospitals within the healthcare industry, including the manufacturers of drugs, devices and medical supplies. The act requires manufacturers such as Bioverativ to report payments and other transfers of value made to U.S. healthcare professionals (HCPs) and healthcare organizations (HCOs) to the federal government.
Along with other related U.S. state-specific transparency requirements, Bioverativ is committed to capturing comprehensive data to meet our obligation. As is required, we must report payments and in-kind items such as food, reprints and travel costs, regardless of the monetary value.
The Centers for Medicare & Medicaid Services (CMS) has been charged with implementing the Physician Payments Sunshine Act. All data is collected and made publicly accessible via CMS’s Open Payments Program.